1-butyl-3-(naphthalen-1-yl)urea | 108619-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-butyl-3-(naphthalen-1-yl)urea
• 英文别名: N-butyl-N'-[1]naphthyl-urea；N-Butyl-N'-[1]naphthyl-harnstoff；1-butyl-3-naphthalen-1-ylurea
• CAS: 108619-31-4
• 化学式: C₁₅H₁₈N₂O
• mdl: MFCD00087826
• 分子量: 242.321
• InChiKey: KGTCAUPNMGXMDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.266
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-butyl-3-(naphthalen-1-yl)urea 、 n-octyltriethylammonium bromide 以 氘代氯仿 为溶剂， 生成
  参考文献：
  名称：

  柱[5]芳烃基异二位主体的合成及其与正辛基三乙基铵盐的络合

  摘要：

  设计并制备了一种新的含有尿素阴离子识别位点的基于柱[5]芳烃的异双位受体。结果表明，脲基团的引入显着提高了对氯仿中不同抗衡离子的正辛基三乙基铵盐的结合亲和力，因为相应的单位主体 1,4-二甲氧基柱[5]芳烃与这些客体显示出弱的络合。研究了尿素单元的重要作用，结果表明尿素基团和大环单元不仅为客体提供了定位的结合位点，而且还协同作用于结合这些客体。

  DOI：

  10.1002/ejoc.201201590
• 作为产物：
  描述：

  1-萘胺 、 异氰酸正丁酯 以 乙醇 为溶剂， 以87%的产率得到1-butyl-3-(naphthalen-1-yl)urea
  参考文献：
  名称：

  Anion recognition by 2,2′-binaphthalene derivatives bearing urea and thiourea groups at 8- and 8′-positions by UV–vis and fluorescence spectroscopies

  摘要：

  Synthesis and anion recognition properties of 2,2'-binaphthalene derivatives bearing two thiourea (1) and urea (2) groups at 8- and 8'-positions were studied. The structure of receptor 1 was determined by Xray crystallography. UV-vis spectra of the receptors showed characteristic changes around 300-400 nm through isosbestic points upon the addition of biologically relevant anions such as acetate, dihydrogenphosphate, and chloride in MeCN and DMSO due to restriction of the rotation around the single bond connecting two naphthyl moieties by cooperative guest binding of two recognition sites. Job's plots showed 1:1 complexation for guest anions. The fluorescence quantum yields of free form of 1 and 2 in MeCN were determined to be 0.021 and 0.57, respectively. The fluorescence intensities of the receptors diminished upon the addition of anions in MeCN. The association constants of receptors 1 and 2 were one or two orders of magnitude greater than the corresponding monothiourea and urea receptors 3 and 4 indicating cooperative hydrogen bonding with guest anions. The selectivity trends of association of anions were F->AcO->H2PO4->Cl->>HSO4- approximate to NO3- approximate to Br- approximate to l(-) for 1, and F->AcO- approximate to Cl->H2PO4-> Br->HSO4->l(-) approximate to NO3- for 2. Receptor 2 showed remarkable Cl- selectivity presumably owing to suitable orientation for effective hydrogen bond formation with Cl-. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.12.004

文献信息

• Modulation of anxiety through blockade of anandamide hydrolysis
  申请人：Piomelli Daniele

  公开号：US20090048337A1

  公开（公告）日：2009-02-19

  Fatty acid amide hydrolase inhibitors of the Formula: I. are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

  提供了公式为I的脂肪酸酰胺水解酶抑制剂，其中X为NH，CH2，O或S; Q为O或S; Z为O或N; R为从取代或未取代芳基; 取代或未取代的联苯基; 取代或未取代的萘基; 取代或未取代的苯基; 取代或未取代的三苯基基; 取代或未取代的环烷基，杂环芳基或烷基中选择的芳香基；R1和R2独立地选择自H，取代或未取代的烷基，取代或未取代的杂环烷基，取代或未取代的苯基，取代或未取代的联苯基，取代或未取代的芳基，取代或未取代的杂环芳基的群体中；但如果Z为O，则R1和R2中的一个不存在，如果Z为N，则可选地将R1和R2结合在一起形成取代或未取代的N-杂环或取代或未取代的杂环芳基，与它们各自连接的N原子。提供了包含公式I化合物的药物组合物以及使用它们抑制FAAH和/或治疗食欲障碍，青光眼，疼痛，失眠以及神经和心理障碍，包括焦虑症，癫痫和抑郁症的方法。
• MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS
  申请人：Piomelli Daniele

  公开号：US20120010283A1

  公开（公告）日：2012-01-12

  Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH 2 , O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R 1 and R 2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R 1 and R 2 is absent, and that if Z is N, optionally R 1 and R 2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they are each attached. Pharmaceutical compositions comprising the compounds of Formula I and methods of using them to inhibit FAAH and/or treat appetite disorders, glaucoma, pain, insomnia, and neurological and psychological disorders including anxiety disorders, epilepsy, and depression are provided.

  提供了公式为的脂肪酸酰胺水解酶抑制剂：其中X为NH，CH2，O或S；Q为O或S；Z为O或N；R为从取代或未取代芳基；取代或未取代联苯基；取代或未取代萘基；取代或未取代苯基；取代或未取代三苯基基；取代或未取代环烷基，杂环芳基或烷基中选择的芳香基；R1和R2分别选择自H，取代或未取代烷基，取代或未取代杂环烷基，取代或未取代苯基，取代或未取代联苯基，取代或未取代芳基和取代或未取代杂环芳基的群中；但是如果Z为O，则R1和R2中的一个不存在，如果Z为N，则可选地将R1和R2结合在一起形成取代或未取代的N-杂环或取代或未取代的杂环芳基，与它们各自连接的N原子。提供了包含公式I化合物的制药组合物以及使用它们来抑制FAAH和/或治疗食欲障碍，青光眼，疼痛，失眠以及神经和心理障碍，包括焦虑症，癫痫和抑郁症的方法。
• NITROGENEOUS TRICYCLIC COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1829876A1

  公开（公告）日：2007-09-05

  A novel compound represented by the following formula (1) or a salt thereof [wherein R1, R5, R6, R7, and R8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X1···X2 represents -CH(R2)-CH(R3)-, -CH(R2)-CH(R3)-CH(R4)-, -C(R2)=C(R3)-, or -C(R2)=C(R3)-CH(R4)- (R2, R3, and R4 represent hydrogen atom, or an alkyl group); A1, A11, A2, and A21 represent hydrogen atom, or an alkyl group; Y represents -CH(A3)-, -CH(A3)-C(A4)(A41)-, -CH(A3)-C(A4)(A41)-C(A5)(A51)-, or a single bond (A3, A4, A41, A5, and A51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or -N(A6)(A61) (As represents hydrogen atom, or an alkyl group, and A61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  由下式(1)代表的新型化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1---X2代表-CH(R2)-CH(R3)-、-CH(R2)-CH(R3)-CH(R4)-、-C(R2)=C(R3)-或-C(R2)=C(R3)-CH(R4)-（R2、R3和R4代表氢原子或烷基）；A1、A11、A2和A21代表氢原子或烷基；Y 代表 -CH(A3)-、-CH(A3)-C(A4)(A41)-、-CH(A3)-C(A4)(A41)-C(A5)(A51)- 或单键（A3、A4、A41、A5 和 A51 代表氢原子或烷基），Z 代表羟基或 -N(A6)(A61) （As 代表氢原子、或烷基，A61 代表氢原子、烷基、取代的烷基等）]，具有有效抑制肌球蛋白调节轻链磷酸化的作用。
• Boehmer, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 379,383
  作者：Boehmer

  DOI：——

  日期：——
• 4"-DEOXY-4"-(S)-AMINO AVERMECTIN DERIVATIVES
  申请人：Merial Limited

  公开号：EP1421094B1

  公开（公告）日：2008-10-15